<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29020023</article-id><article-id pub-id-type="pmc">5636096</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0185412</article-id><article-id pub-id-type="publisher-id">PONE-D-16-45844</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Psychometrics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Psychology</subject><subj-group><subject>Psychometrics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Liver Diseases</subject><subj-group><subject>Cirrhosis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Science</subject><subj-group><subject>Cognitive Neuroscience</subject><subj-group><subject>Reaction Time</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Neuroscience</subject><subj-group><subject>Reaction Time</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Adverse Events</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Research Design</subject><subj-group><subject>Pilot Studies</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (Mathematics)</subject><subj-group><subject>Statistical Data</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Engineering and Technology</subject><subj-group><subject>Electronics</subject><subj-group><subject>Comparators</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Science</subject><subj-group><subject>Cognitive Neuroscience</subject><subj-group><subject>Cognitive Neurology</subject><subj-group><subject>Cognitive Impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Neuroscience</subject><subj-group><subject>Cognitive Neuroscience</subject><subj-group><subject>Cognitive Neurology</subject><subj-group><subject>Cognitive Impairment</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cognitive Neurology</subject><subj-group><subject>Cognitive Impairment</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention&#x02014;A pilot study</article-title><alt-title alt-title-type="running-head">Measuring treatment response in minimal hepatic encephalopathy using continuous reaction time test&#x02014;An RCT</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0586-8549</contrib-id><name><surname>Lauridsen</surname><given-names>M. M.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Mikkelsen</surname><given-names>S.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Svensson</surname><given-names>T.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Holm</surname><given-names>J.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kl&#x000fc;ver</surname><given-names>C.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gram</surname><given-names>J.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vilstrup</surname><given-names>H.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schaffalitzky de Muckadell</surname><given-names>O. B.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Gastroenterology, Hospital of South West Jutland, Esbjerg, Denmark</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department for Gastrointestinal diseases, Odense University Hospital, Sdr. Boulevard 29, Odense C, Denmark</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Endocrinology, Hospital of South West Jutland, Esbjerg, Denmark</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kim</surname><given-names>Do Young</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Yonsei University College of Medicine, REPUBLIC OF KOREA</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>MM Lauridsen has given lectures paid by Norgine, MM Lauridsen has a consultant agreement with Umecrine Cognition, MM Lauridsen is on the steering committee in the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><corresp id="cor001">* E-mail: <email>mette.enok.munk.lauridsen@rsyd.dk</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>10</issue><elocation-id>e0185412</elocation-id><history><date date-type="received"><day>7</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>2</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Lauridsen et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Lauridsen et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0185412.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Minimal hepatic encephalopathy (MHE) is clinically undetectable and the diagnosis requires psychometric tests. However, a lack of clarity exists as to whether the tests are in fact able to detect changes in cognition.</p></sec><sec id="sec002"><title>Aim</title><p>To examine if the continuous reaction time test (CRT) can detect changes in cognition with anti-HE intervention in patients with cirrhosis and without clinically manifest hepatic encephalopathy (HE).</p></sec><sec id="sec003"><title>Methods</title><p>Firstly, we conducted a reproducibility analysis and secondly measured change in CRT induced by anti-HE treatment in a randomized controlled pilot study: We stratified 44 patients with liver cirrhosis and without clinically manifest HE according to a normal (n = 22) or abnormal (n = 22) CRT. Each stratum was then block randomized to receive multimodal anti-HE intervention (lactulose+branched-chain amino acids+rifaximin) or triple placebos for 3 months in a double-blinded fashion. The CRT is a simple PC-based test and the test result, the CRT index (normal threshold &#x0003e; 1.9), describes the patient&#x02019;s stability of alertness during the 10&#x02013;minute test. Our study outcome was the change in CRT index in each group at study exit. The portosystemic encephalopathy (PSE) test, a paper-and-pencil test battery (normal threshold above -5), was used as a comparator test according to international guidelines.</p></sec><sec id="sec004"><title>Results</title><p>The patients with an abnormal CRT index who were randomized to receive the active intervention normalized or improved their CRT index (mean change 0.92 &#x000b1; 0.29, p = 0.01). Additionally, their PSE improved (change 3.85 &#x000b1; 1.83, p = 0.03). There was no such effect in any of the other study groups.</p></sec><sec id="sec005"><title>Conclusion</title><p>In this cohort of patients with liver cirrhosis and no manifest HE, the CRT identified a group in whom cognition improved with intensive anti-HE intervention. This finding infers that the CRT can detect a response to treatment and might help in selecting patients for treatment.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004196</institution-id><institution>Odense Universitetshospital</institution></institution-wrap></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0586-8549</contrib-id><name><surname>Lauridsen</surname><given-names>Mette Munk</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Hospital of Southwest Jutland</institution></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0586-8549</contrib-id><name><surname>Lauridsen</surname><given-names>Mette Munk</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Esbjergfonden</institution></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0586-8549</contrib-id><name><surname>Lauridsen</surname><given-names>Mette Munk</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution>Karola J&#x000f8;rgensens Fond</institution></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0586-8549</contrib-id><name><surname>Lauridsen</surname><given-names>Mette Munk</given-names></name></principal-award-recipient></award-group><funding-statement>MM Lauridsen and the research project were funded by the following public Danish funds: The research fund at The Hospital of South West Jutland Odense University Hospital Free Research Fund, <ext-link ext-link-type="uri" xlink:href="http://www.ouh.dk/wm379847">http://www.ouh.dk/wm379847</ext-link>; University of Southern Denmark PhD, Scholarship, <ext-link ext-link-type="uri" xlink:href="http://www.sdu.dk/forskning/phd/phd_skoler/phdskolensundhedsvidenskab">http://www.sdu.dk/forskning/phd/phd_skoler/phdskolensundhedsvidenskab</ext-link>; Esbjergfonden, Karola J&#x000f8;rgensens Fond.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="5"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>The term minimal hepatic encephalopathy (MHE) denotes cognitive deficits in a patient with liver disease that are undetectable at clinical encounters. A MHE diagnosis, therefore, requires psychometric tests. The prevalence of MHE is very high in cirrhosis patients; i.e., present in approximately 50%[<xref rid="pone.0185412.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0185412.ref002" ref-type="bibr">2</xref>]. The condition is associated with severe loss of quality of life and markedly increased risks of clinically manifest HE that, in itself, is associated with increased mortality. Of note, MHE is usually treatable and treatment may improve all these untoward effects [<xref rid="pone.0185412.ref003" ref-type="bibr">3</xref>].</p><p>Despite the positive effects of diagnosing and treating MHE, only a few centres do so routinely[<xref rid="pone.0185412.ref004" ref-type="bibr">4</xref>]. One important hindrance is that it remains unclear if the necessary psychometric tests are clinically meaningful for predicting a positive treatment effect; i.e., knowledge is lacking about the test&#x02019;s ability to predict cognitive improvements that are taken to be the basis of improved outcomes with treatment. Consequently, the basis on which patients can be selected for treatment is insufficient.</p><p>The underlying problem is that there is no gold standard for the diagnosis or grading of MHE. In specialist clinical centres, a few psychometric tests are used routinely in different combinations to diagnose MHE, but the test results are widely discordant in the individual patients [<xref rid="pone.0185412.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0185412.ref007" ref-type="bibr">7</xref>]&#x02014;although the group MHE prevalence with each one of the tests is similar. It remains uncertain how any of these tests should be validated for its ability to correctly identify patients with liver cirrhosis who may be expected to benefit from treatment.</p><p>We took advantage of the clinical reports on positive effects of MHE treatments to utilize anti-HE intervention as a tool for validation of a psychometric test: the continuous reaction time (CRT) test [<xref rid="pone.0185412.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0185412.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0185412.ref009" ref-type="bibr">9</xref>]. To have the strongest possible tool, we used the treatment principles reported to be efficacious in HE treatment in combination, viz. lactulose + branched amino acids + rifaximin. To avoid possible pitfalls; i.e., confounding due to the complex aetiology of MHE and its fluctuating time course, we used the intervention in a double blinded randomized prospective fashion in cirrhosis patients who did not present manifest HE.</p><p>The psychometric test we evaluated in this way, the CRT, is a simple PC-based performance test measuring the important cognitive ability of being able to deliver stable motor reactions to sensory stimuli&#x02014;an ability of obvious importance for every-day living. In Scandinavia, this test is established for clinical routine use in the management of MHE. In the pilot study we present here, we also applied the portosystemic encephalopathy (PSE) test, a paper-and-pencil test recommended as an international comparator test for MHE studies.</p><p>Our hypothesis was that the CRT is able to identify patients with liver cirrhosis who improve cognition by anti-HE intervention. The aim of the study was to measure the CRT before and after such intervention vs. placebo.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Patients and methods</title><sec id="sec008"><title>Patients</title><sec id="sec009"><title>Reproducibility&#x02013;cohort</title><p>Twenty-two patients with liver cirrhosis underwent repeated CRT testing to assess CRT reproducibility. They were included from 2 Danish sites (Odense University Hospital and Hospital of South West Jutland) during October 2012 without clinically manifest HE and were all tested twice before and twice after noon on two consecutive days reaching a total of 8 measurements per patient within 48 hours. Patients were aged 61 years (range 42&#x02013;73 years), 18 were men, mean MELD score was 6.12 (range 6&#x02013;16) and all had alcoholic cirrhosis. All patients were tested between 8.00 and 14.00 in an undisturbed location by one of 3 trained operators. All participants gave their informed written consent and The Regional Scientific Ethical Committee for Southern Denmark approved the study protocol (Protocol number S-20120196). In- and exclusion criteria cf. below.</p></sec><sec id="sec010"><title>The RCT-cohort</title><p>The inclusion criteria were age above 18 years, diagnosis of liver cirrhosis and absence of clinically manifest HE. From November 2013 to December 2014, we enrolled 44 such patients from the Hospital of Southwest Jutland (n = 23) and Odense University Hospital (n = 21; <xref ref-type="fig" rid="pone.0185412.g001">Fig 1</xref>). They were all cleared of manifest HE by experienced hepatologists. Liver cirrhosis was diagnosed by liver biopsy (19/44) or via unequivocal clinical, biochemical and ultrasonic findings. The exclusion criteria were HE of West Haven Grade 1 or more; organic brain disease; i.e., dementia or prior cerebrovascular disease; ongoing use of alcohol or psychoactive medication; severe hyponatremia (P-Na &#x0003c; 125 &#x003bc;mol/L), renal failure (P-creatinine &#x0003e; 150 &#x003bc;mol/L) or myxoedema; ongoing anti-HE treatment; acute bacterial infections, and sepsis or gastro-intestinal bleeding within a week of the test day. The included patients were, on average, aged 61.1 years (range 44&#x02013;77 years), had 11.5 years (range 4&#x02013;12 years) of formal education, 31 were men and alcohol was the dominant aetiology (37/44); 12 had previously manifest HE and 4 had a TIPS (2 in each treatment arm). All but 6 participants had previously participated in a cross-sectional study published previously (10), but upon inclusion in the study we present here they were psychometrically retested. All patients were tested with the two psychometric tests (CRT and PSE) at inclusion and at follow-up visits. Participants also completed a Sickness Impact Profile (SIP) questionnaire on their quality of life within the last 24 hours. Study entry characteristics of strata and randomized groups are summarized in Tables <xref ref-type="table" rid="pone.0185412.t001">1</xref> and <xref ref-type="table" rid="pone.0185412.t002">2</xref>. The study time was 3 months and the patients were further followed up for an average of 10 months and episodes of manifest HE, hospital admissions, and deaths were registered. The descriptive entry CRT and PSE data were published earlier, apart from 6 new participants [<xref rid="pone.0185412.ref010" ref-type="bibr">10</xref>].</p><fig id="pone.0185412.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185412.g001</object-id><label>Fig 1</label><caption><title>Patient flow through the study.</title><p>A total of 44 patients were prospectively included and stratified according to a CRT index below or at 1.9 (abnormal) or above (normal). Patients were then block randomized into groups to receive either triple-active anti-HE intervention or triple placebo. We followed them for 3 months.</p></caption><graphic xlink:href="pone.0185412.g001"/></fig><table-wrap id="pone.0185412.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185412.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics for patients on active and placebo intervention.</title></caption><alternatives><graphic id="pone.0185412.t001g" xlink:href="pone.0185412.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Active N = 22</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Placebo N = 22</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years, mean and range)</td><td align="center" rowspan="1" colspan="1">59.6 (44&#x02013;72)</td><td align="center" rowspan="1" colspan="1">61.1 (49&#x02013;77)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male/female</td><td align="center" rowspan="1" colspan="1">15/7</td><td align="center" rowspan="1" colspan="1">16/6</td></tr><tr><td align="left" rowspan="1" colspan="1">Cirrhosis aetiology<break/>Alc/Alc+HCV/HCV/unknown</td><td align="center" rowspan="1" colspan="1">19/0/1/2</td><td align="center" rowspan="1" colspan="1">18/2/0/2</td></tr><tr><td align="left" rowspan="1" colspan="1">White/blue collar</td><td align="center" rowspan="1" colspan="1">5/17</td><td align="center" rowspan="1" colspan="1">8/14</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years, mean and range)</td><td align="center" rowspan="1" colspan="1">11.2 (4&#x02013;18)</td><td align="center" rowspan="1" colspan="1">11.7 (7&#x02013;18)</td></tr><tr><td align="left" rowspan="1" colspan="1">MELD score (mean and range)</td><td align="center" rowspan="1" colspan="1">12.2 (6&#x02013;20)</td><td align="center" rowspan="1" colspan="1">12.6 (7&#x02013;24)</td></tr><tr><td align="left" rowspan="1" colspan="1">Child Pugh Score (mean and range)</td><td align="center" rowspan="1" colspan="1">8.0 (5&#x02013;15)</td><td align="center" rowspan="1" colspan="1">7.4 (5&#x02013;12)</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous OHE</td><td align="center" rowspan="1" colspan="1">6/22</td><td align="center" rowspan="1" colspan="1">6/22</td></tr><tr><td align="left" rowspan="1" colspan="1">P-ammonia (&#x003bc;mol/L, mean and range)</td><td align="center" rowspan="1" colspan="1">40.0 (21&#x02013;137)</td><td align="center" rowspan="1" colspan="1">39 (14&#x02013;73)</td></tr><tr><td align="left" rowspan="1" colspan="1">Entry CRT index (mean and range)</td><td align="center" rowspan="1" colspan="1">1.7 (0.9&#x02013;2.4)</td><td align="center" rowspan="1" colspan="1">1.8 (0.5&#x02013;2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Entry PHES (mean and range)</td><td align="center" rowspan="1" colspan="1">-8.0 (-15&#x02013; -1)</td><td align="center" rowspan="1" colspan="1">-5.9 (-16&#x02013; -2)</td></tr><tr><td align="left" rowspan="1" colspan="1">PHES and CRT agreement on MHE diagnosis</td><td align="center" rowspan="1" colspan="1">14/22</td><td align="center" rowspan="1" colspan="1">13/22</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Abbreviations: CRT, continuous reaction time; PHES, portosystemic hepatic encephalopathy score; MELD, model for end stage liver disease; HE, hepatic encephalopathy; OHE, overt hepatic encephalopathy; MHE, minimal hepatic encephalopathy.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0185412.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185412.t002</object-id><label>Table 2</label><caption><title>Baseline characteristics for patients on active and placebo intervention stratified by continuous reaction time index (CRT index) at inclusion.</title></caption><alternatives><graphic id="pone.0185412.t002g" xlink:href="pone.0185412.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" style="background-color:#D9D9D9" colspan="1"/><th align="center" colspan="2" style="background-color:#D9D9D9" rowspan="1">CRT index &#x0003c; 1.9 (abnormal)</th><th align="center" colspan="2" style="background-color:#D9D9D9" rowspan="1">CRT index &#x02265; 1.9<break/>(normal)</th></tr><tr><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Active<break/>N = 11</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Placebo<break/>N = 11</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Active<break/>N = 11</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Placebo<break/>N = 11</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years, mean and range)</td><td align="center" rowspan="1" colspan="1">60.3 (44&#x02013;70)</td><td align="center" rowspan="1" colspan="1">64.2 (49&#x02013;77)</td><td align="center" rowspan="1" colspan="1">59.0 (44&#x02013;72)</td><td align="center" rowspan="1" colspan="1">57.9 (50&#x02013;67)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female/male</td><td align="center" rowspan="1" colspan="1">3/8</td><td align="center" rowspan="1" colspan="1">2/9</td><td align="center" rowspan="1" colspan="1">4/7</td><td align="center" rowspan="1" colspan="1">4/7</td></tr><tr><td align="left" rowspan="1" colspan="1">White/blue collar</td><td align="center" rowspan="1" colspan="1">3/8</td><td align="center" rowspan="1" colspan="1">5/6</td><td align="center" rowspan="1" colspan="1">2/9</td><td align="center" rowspan="1" colspan="1">3/8</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years, mean and range)</td><td align="center" rowspan="1" colspan="1">11.6 (8&#x02013;18)</td><td align="center" rowspan="1" colspan="1">11.9 (7&#x02013;16)</td><td align="center" rowspan="1" colspan="1">10.8 (4&#x02013;14)</td><td align="center" rowspan="1" colspan="1">11.5 (8&#x02013;18)</td></tr><tr><td align="left" rowspan="1" colspan="1">MELD score (mean and range)</td><td align="center" rowspan="1" colspan="1">12.0 (7&#x02013;20)</td><td align="center" rowspan="1" colspan="1">13.9 (7&#x02013;24)</td><td align="center" rowspan="1" colspan="1">12.55 (6&#x02013;20)</td><td align="center" rowspan="1" colspan="1">11.45 (7&#x02013;19)</td></tr><tr><td align="left" rowspan="1" colspan="1">Child Pugh Score (mean and range)</td><td align="center" rowspan="1" colspan="1">7.8 (6&#x02013;16)</td><td align="center" rowspan="1" colspan="1">7.8 (5&#x02013;12)</td><td align="center" rowspan="1" colspan="1">8.4(5&#x02013;12)</td><td align="center" rowspan="1" colspan="1">6.9 (5&#x02013;9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous OHE</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Entry CRT index (mean and range)</td><td align="center" rowspan="1" colspan="1">1.3 (0.9&#x02013;1.7)</td><td align="center" rowspan="1" colspan="1">1.4 (0.5&#x02013;1.8)</td><td align="center" rowspan="1" colspan="1">2.1 (1.9&#x02013;2.4)</td><td align="center" rowspan="1" colspan="1">2.1 (1.9&#x02013;2.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Entry PHES (mean and range)</td><td align="center" rowspan="1" colspan="1">-8.5 (-15&#x02013; -5)</td><td align="center" rowspan="1" colspan="1">-6.7 (-16&#x02013; -2)</td><td align="center" rowspan="1" colspan="1">-7.6 (-13&#x02013; -1)</td><td align="center" rowspan="1" colspan="1">-5.1 (-13&#x02013; -1)</td></tr><tr><td align="left" rowspan="1" colspan="1">PHES and CRT agreement on MHE diagnosis</td><td align="center" rowspan="1" colspan="1">11/11</td><td align="center" rowspan="1" colspan="1">8/11</td><td align="center" rowspan="1" colspan="1">3/11</td><td align="center" rowspan="1" colspan="1">5/11</td></tr><tr><td align="left" rowspan="1" colspan="1">P-ammonia (&#x003bc;mol/L, mean and range)</td><td align="center" rowspan="1" colspan="1">57 (25&#x02013;137)</td><td align="center" rowspan="1" colspan="1">34 (14&#x02013;65)</td><td align="center" rowspan="1" colspan="1">43 (22&#x02013;41)</td><td align="center" rowspan="1" colspan="1">29 (15&#x02013;73)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Abbreviations: CRT, continuous reaction time; PHES, portosystemic hepatic encephalopathy score; MELD, model for end stage liver disease; HE, hepatic encephalopathy; OHE, overt hepatic encephalopathy; MHE, minimal hepatic encephalopathy.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec011" sec-type="materials|methods"><title>Methods</title><sec id="sec012"><title>The continuous reaction time test (CRT)</title><p>The test is PC-based and requires a standard laptop, simple software, headphones, and a handheld trigger button (EKHO, <ext-link ext-link-type="uri" xlink:href="http://www.Bitmatic.com">www.Bitmatic.com</ext-link>, Aarhus, Denmark). After a 2&#x02013;minute instruction, the patient is left alone and undisturbed to complete the 10-minute test during which the patient responds to 150 sound stimuli (beeps at 500 Hz and 80 dB) by pressing a button. They are delivered at random intervals from 2 to 6 seconds and the patient is instructed to press the button as soon the beep is heard. The software registers the response times and calculates the CRT index (the ratio: 50 percentile/[90 minus 10 percentile]). The method measures and combines motor reaction speed, sustained attention, and inhibitory control, which are all key abilities in daily life functioning [<xref rid="pone.0185412.ref011" ref-type="bibr">11</xref>].</p><p>The group change in CRT index was the primary study outcome. The CRT index is not affected by age, gender, educational level or intelligence [<xref rid="pone.0185412.ref012" ref-type="bibr">12</xref>&#x02013;<xref rid="pone.0185412.ref015" ref-type="bibr">15</xref>]. The established threshold for normal values is a CRT index of 1.9. An index below 1.9 reflects poor reaction time <italic>stability</italic> and may indicate MHE in patients with cirrhosis. The threshold is based on prior studies designed to discriminate between HE patients, controls, and patients with organic brain damage with a sensitivity and specificity above 90%[<xref rid="pone.0185412.ref016" ref-type="bibr">16</xref>].</p></sec><sec id="sec013"><title>The portosystemic encephalopathy test (PSE)</title><p>This was a secondary study outcome. The test is a paper-and-pencil test consisting of 5 sub-tests: Digit Symbol test (DST), Number Connection Test A (NCT-A), Number Connection Test B (NCT-B), Serial Dotting Test (SDOT), and Line Tracing Test (LTT, time and errors). Completing all sub-tests takes approximately 15 minutes and the presence of staff for guidance and timing is required. Calculation of the final test result using age-adjusted norms takes another 5 minutes. The test score is calculated from the time (seconds) spent on each sub-test, which is converted into a score that ranges between -3 and 1. The LTT is converted into 2 scores&#x02014;a time score and an error score. A score of 0 is given for a performance within +/- 1 SD. The total test score, the portosystemic hepatic encephalopathy score (PHES), is the sum of the scores. A result below -4 is abnormal and may indicate MHE in liver patients. Danish norm data (personal communication) were applied. The test measures attention, working speed and accuracy, visual orientation, and visuo-spatial construction [<xref rid="pone.0185412.ref005" ref-type="bibr">5</xref>]. Multiple versions of the test battery are available to prevent learning effects with repeated testing [<xref rid="pone.0185412.ref017" ref-type="bibr">17</xref>].</p></sec></sec></sec><sec id="sec014"><title>Interventions</title><p>After initial testing and stratification according to the CRT index, the patients were block randomized into two groups to receive either triple-active anti-HE intervention or triple placebo for 3 months. The patients randomized to active intervention received 66.7% lactulose syrup (Medilax, up to 75 mL/day), branched-chain amino acids (Bramino, powder formulation, 17 g/day) and rifaximin (Xifaxan, tablets, 550 mg b.i.d.). The triple placebo regimen consisted of placebo to lactulose (50% glucose syrup), placebo to branched-chain amino acids (alanine powder) and placebo to rifaximin (inactive tablets identical to the active tablets). Patients received oral and written information about possible adverse effects of the medications. The effect of the interventions was measured after study end. A protocol summary is available in <xref ref-type="supplementary-material" rid="pone.0185412.s001">S1 Text</xref> and the full protocol in <xref ref-type="supplementary-material" rid="pone.0185412.s002">S2 Text</xref>.</p></sec><sec id="sec015"><title>Randomization</title><p>The Odense University Hospital Pharmacy boxed active and placebo medications in numbered packages and intervention assignment was obtained from a computer-generated randomization list in blocks of 22. All items were labelled with only the patient and study number (numbers 1&#x02013;44). Boxes numbered 1&#x02013;22 contained 11 sets of active medicine and 11 sets of placebo medicine in random sequence and were consecutively assigned to the stratum of participants with a CRT index &#x0003c; 1.9. The boxes numbered 23&#x02013;44 likewise contained the same sets as the first boxes and were sequentially assigned to the stratum of participants with a CRT index greater than or equal to 1.9. In this way, all the patients, including those with a CRT index within the normal range (up to a CRT index of 2.5), randomly received active intervention or placebos. The study participants and all staff were blinded until all data were collected.</p></sec><sec id="sec016"><title>Ethics</title><p>There were no reported serious adverse effects for any of the components of the active and placebo interventions. We considered it ethically acceptable to administer the interventions to both cirrhosis patients with and without psychometric signs of MHE and without the aim of documenting a clinical outcome benefit. The potential benefit to future patients lies in the prospective of improving the possibilities of identifying such patients who can be expected to improve their cognition by treatment. The study principle, methods and protocol complied with the 1975 Declaration of Helsinki and was approved by the Danish National Committee on Health Research Ethics and registered at clinicaltrial.gov (Identifier: NCT01773538). All participating patients gave their informed written consent.</p></sec><sec id="sec017"><title>Statistical analysis</title><p>RCT data and reproducibility data are available in <xref ref-type="supplementary-material" rid="pone.0185412.s003">S1 Data</xref> and <xref ref-type="supplementary-material" rid="pone.0185412.s004">S2 Data</xref>. In the reproducibility analysis we assessed the between-subject variations by calculating group means and scatter (= 2SD). Within subject reproducibility was assessed by the mean intra-subject scatter of CRTindices.</p><p>For the RCT our hypothesis was that patients randomized to active intervention would obtain an improvement in the CRT index significantly greater than that resulting from the placebo intervention. Accordingly, our primary outcome was the difference in mean CRT index <underline>change</underline> between active and placebo groups. We wanted a type I error of 5% and a type II error of 15% (power 85%). The expected dropout rate was set at 20%. We assumed that the standard deviation of repeated measurements is a reasonable estimate of the unknown standard deviation of <italic>changes</italic> in CRT index and the desired effect size was set at 0.68. We found that 6 patients were needed per group. This number was increased to 9 as the true SD of changes in CRT index most likely is larger. As we ultimately decided to have 2 stratae in each group we included 36 patients plus 8 to take drop outs in to account i.e. a total of 44&#x02013;22 in each treatment arm [<xref rid="pone.0185412.ref018" ref-type="bibr">18</xref>]. The CRT index data showed Gaussian distribution as evaluated by the histogram and using the Shapiro-Wilk test we found a non-significant p-value (p = 0.41) indicating that the sample came from a normally distributed population [<xref rid="pone.0185412.ref019" ref-type="bibr">19</xref>]. Student&#x02019;s t-test was therefore used to test for intra- and inter-group differences in CRT index. For the PHES Wilcoxon rank-sum test was used. We used one-sided p-values in the comparison of pre and post treatment results in the groups receiving active intervention as we assumed to know the direction of the CRT index and PHES change. In all other cases two-sided p-values were used. Difference between proportions was assessed using Fisher&#x02019;s exact test. Statistical analysis was performed using Prism 6 GraphPad for Mac OS X.</p></sec><sec sec-type="results" id="sec018"><title>Results</title><sec id="sec019"><title>Reproducibility</title><p>Results are displayed in <xref ref-type="fig" rid="pone.0185412.g002">Fig 2</xref>. Within subject SD showed a negligible decrease with increasing age i.e. decreasing with approximately 0.01 per decade. We chose not to take age in to account and found that in cirrhosis patients the group mean CRTindex was 2.35 (SD 0.61, 95%CI 2.3&#x02013;2.4, range 0.67&#x02013;3.87). The within-subject mean SD was 0.34. Accordingly, a CRTindex change of more than 0.68 (2SD) in a cirrhosis patient can be taken to reflect a significant change in CRTindex. Time of day did not influence the CRTindex or mean in either group.</p><fig id="pone.0185412.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185412.g002</object-id><label>Fig 2</label><caption><title>Data from 22 patients with liver cirrhosis who all underwent 8 repeated continuous reaction time (CRT) measurements: 4 measurements on to consecutive days.</title></caption><graphic xlink:href="pone.0185412.g002"/></fig></sec><sec id="sec020"><title>RCT</title><p>Seventeen patients with an abnormal CRT index below 1.9 (7 actively treated, 10 placebo) and 16 with a normal CRT index &#x02265;1.9 (6 actively treated, 10 placebo) completed the 3-month study (<xref ref-type="fig" rid="pone.0185412.g001">Fig 1</xref>).</p><sec id="sec021"><title>Effects of the anti&#x02013;HE intervention on the CRT index according to active vs. placebo</title><p>Baseline characteristics are shown in <xref ref-type="table" rid="pone.0185412.t001">Table 1</xref>. The mean CRT index improved from 1.7 to 2.2 (p = 0.02) in the patients on active intervention and remained stable at 1.8 in the placebo group (<xref ref-type="table" rid="pone.0185412.t003">Table 3</xref>). There was a marginal difference in the exit CRT index values between the active and placebo groups (2.2 vs. 1.8, p = 0.07). There was also a marginal difference in the mean CRT index change between the patients on active and placebo intervention (a mean CRT index change of 0.50&#x000b1;0.20 vs. 0.13&#x000b1;0.12, p = 0.06). The mean PHES improved from -8.0 to -5.0 in the patients on active intervention (p = 0.02). There was no difference in exit PHES between the active and placebo group (-5.0 vs. -5.5, p = 0.40) but the mean PHES change was larger in the active group (3.9&#x000b1;0.9 vs. -0.8&#x000b1;0.8, p = 0.02).</p><table-wrap id="pone.0185412.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185412.t003</object-id><label>Table 3</label><caption><title>Psychometric results and changes at the 3-month follow up in the active and placebo intervention groups.</title></caption><alternatives><graphic id="pone.0185412.t003g" xlink:href="pone.0185412.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Active<break/>N = 13</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Placebo N = 20</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">P</th></tr><tr><th align="left" colspan="4" style="background-color:#D9D9D9" rowspan="1">Psychometry at 3-month follow-up</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CRT index (mean and range)</td><td align="center" rowspan="1" colspan="1">2.2 (1.6&#x02013;3.4)</td><td align="center" rowspan="1" colspan="1">1.8 (0.9&#x02013;3.3)</td><td align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x00394;CRT index (mean change and SEM)</td><td align="center" rowspan="1" colspan="1">0.50 &#x000b1; 0.20</td><td align="center" rowspan="1" colspan="1">0.13 &#x000b1; 0.12</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Normalized CRT index</td><td align="center" rowspan="1" colspan="1">5/7 (71%)</td><td align="center" rowspan="1" colspan="1">3/10 (30%)</td><td align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">PHES at 3 months (mean and range)</td><td align="left" rowspan="1" colspan="1">-5.0 (-16&#x02013; &#x02013;1)</td><td align="center" rowspan="1" colspan="1">-5.5 (-15&#x02013;1)</td><td align="center" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x00394;PHES (mean change and SEM)</td><td align="center" rowspan="1" colspan="1">3.9 &#x000b1; 0.9</td><td align="center" rowspan="1" colspan="1">0.8 &#x000b1; 0.8</td><td align="center" rowspan="1" colspan="1"><bold>0.02</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Normalized PHES</td><td align="center" rowspan="1" colspan="1">6/7 (85%)</td><td align="center" rowspan="1" colspan="1">3/5 (60%)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>Abbreviations: CRT, continuous reaction time; PHES, portosystemic hepatic encephalopathy score</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec022"><title>Effects of the anti&#x02013;HE intervention on the CRT index according to the entry CRT index</title><p>The stratum with an abnormal baseline CRT index: Baseline characteristics are displayed in <xref ref-type="table" rid="pone.0185412.t002">Table 2</xref> and results after 3 months of intervention in <xref ref-type="table" rid="pone.0185412.t004">Table 4</xref>. The patients with an abnormal entry CRT index and randomized to the active intervention improved their CRT index from 1.3 to 2.3 (p = 0.01) and, thus as a group, (5 of 7 patients) normalized their CRT index. No such improvement was seen in the corresponding patients randomized to the placebo intervention (1.4 to 1.6, p = 0.15) who, as a group, continued to have an abnormal CRT index (<xref ref-type="table" rid="pone.0185412.t004">Table 4</xref>). Likewise, the mean CRT index change was larger in the patients on active intervention (0.92 &#x000b1; 0.29, 95%CI -0.08&#x02013;0.68) vs. those on placebos (0.25 &#x000b1; 0.18, 95%CI -0.27&#x02013;1.56; active vs. placebo p = 0.03; <xref ref-type="table" rid="pone.0185412.t004">Table 4</xref>). The PHES also improved in the patients with an abnormal entry CRT index on active intervention (a mean entry PHES -9.8 vs. a mean exit value -6.7, p = 0.003). Again, the mean PHES change was larger in the active treated vs. placebo groups (4.6 &#x000b1; 1.3, 95%CI 1.2&#x02013;7.9 vs. -0.20&#x000b1;0.13, 95%CI -3.2&#x02013;2.7, p = 0.03; <xref ref-type="table" rid="pone.0185412.t004">Table 4</xref>) and in all cases concomitant with the change in CRT.</p><table-wrap id="pone.0185412.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185412.t004</object-id><label>Table 4</label><caption><title>Main results in the strata with CRT index &#x0003c;1.9 (abnormal) and 1.9 (normal).</title><p>For continuous variables, the mean and range or standard error of the mean are given.</p></caption><alternatives><graphic id="pone.0185412.t004g" xlink:href="pone.0185412.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/><th align="center" colspan="3" style="background-color:#D9D9D9" rowspan="1">CRT index &#x0003c; 1.9 (abnormal)</th><th align="center" colspan="3" style="background-color:#D9D9D9" rowspan="1">CRT index &#x02265; 1.9 (normal)</th></tr><tr><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">3-month follow-up</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Active<break/>n = 7</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Placebo<break/>n = 10</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">P</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Active<break/>n = 6</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Placebo<break/>n = 10</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CRT index (mean and range)</td><td align="center" rowspan="1" colspan="1">2.3 (1.6&#x02013;3.4)</td><td align="center" rowspan="1" colspan="1">1.6 (0.9&#x02013;2.5)</td><td align="center" rowspan="1" colspan="1"><bold>0.02</bold></td><td align="center" rowspan="1" colspan="1">2.0 (1.7&#x02013;2.7)</td><td align="center" rowspan="1" colspan="1">2.2 (1.4&#x02013;3.3)</td><td align="center" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x00394;CRT index (mean change and SEM)</td><td align="center" rowspan="1" colspan="1">0.92 &#x000b1; 0.29</td><td align="center" rowspan="1" colspan="1">0.25 &#x000b1; 0.18</td><td align="center" rowspan="1" colspan="1"><bold>0.03</bold></td><td align="center" rowspan="1" colspan="1">0.07 &#x000b1; 0.07</td><td align="center" rowspan="1" colspan="1">0.06 &#x000b1; 0.19</td><td align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Normalized CRT index</td><td align="center" rowspan="1" colspan="1">5/7</td><td align="center" rowspan="1" colspan="1">3/10</td><td align="center" rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">PHES at 3 months (mean and range)</td><td align="center" rowspan="1" colspan="1">-3.6 (-9&#x02013; -0)</td><td align="center" rowspan="1" colspan="1">-7.6 (-15&#x02013;0)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">-6.7 (-16&#x02013;3)</td><td align="center" rowspan="1" colspan="1">-3.4 (-11&#x02013;1)</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x00394;PHES (mean change and SEM)</td><td align="center" rowspan="1" colspan="1">4.6 &#x000b1; 1.37</td><td align="center" rowspan="1" colspan="1">-0.20 &#x000b1; 1.32</td><td align="center" rowspan="1" colspan="1"><bold>0.03</bold></td><td align="center" rowspan="1" colspan="1">3.1 &#x000b1; 1.35</td><td align="center" rowspan="1" colspan="1">1.7 &#x000b1; 0.93</td><td align="center" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Normalized PHES</td><td align="center" rowspan="1" colspan="1">4/11</td><td align="center" rowspan="1" colspan="1">1/8</td><td align="center" rowspan="1" colspan="1">0.34</td><td align="center" rowspan="1" colspan="1">2/8</td><td align="center" rowspan="1" colspan="1">2/6</td><td align="left" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">P-ammonia (&#x003bc;mol/L, mean and range)</td><td align="center" rowspan="1" colspan="1">44 (16&#x02013;108)</td><td align="center" rowspan="1" colspan="1">41 (15&#x02013;59)</td><td align="center" rowspan="1" colspan="1">0.82</td><td align="center" rowspan="1" colspan="1">39 (26&#x02013;65)</td><td align="center" rowspan="1" colspan="1">40 (16&#x02013;67)</td><td align="center" rowspan="1" colspan="1">0.96</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>Abbreviations: CRT, continuous reaction time; PHES, portosystemic hepatic encephalopathy score.</p></fn></table-wrap-foot></table-wrap><p>The stratum with a normal baseline CRT index: No change from the baseline CRT index was found in the active or the placebo group. The PSE test also did not change. There was no difference in CRT and PSE changes (<xref ref-type="table" rid="pone.0185412.t004">Table 4</xref>).</p><p>Ammonia and manifest HE episodes: The P-ammonia concentration decreased on average by 22% (from a mean of 57 to 44 &#x003bc;mol/L, p = 0.05) in the group with an abnormal entry CRT index and randomized to active intervention, but such an effect was not observed in any other group. No significant or systematic change in Child Pugh, MELD, or SIP score was observed in either strata or group. CRP remained unchanged in all groups.</p><p>During the post&#x02013;study follow-up, 2 out of 13 in the group receiving active intervention and 4 out of 20 in the placebo group experienced an episode of manifest HE. In the active group, 1 patient died (acute-on-chronic liver failure) while 5 patients in the placebo group died (2 of infection, 1 of heart failure, 1 of variceal bleed, and 1 postoperatively after a case of ileus; p = 0.36).</p><p>Post hoc analysis of psychometric effects according to entry PSE: The patients were primarily stratified according to their CRT index, so the analysis according to PSE is an exploratory secondary analysis. It is based on 25 patients with an abnormal entry PSE, 13 of them receiving the active intervention and 12 of them receiving the placebos. Those on the active intervention improved their CRT index from 1.6&#x000b1;0.4 to 2.2&#x000b1;0.5 (p = 0.02) and PHES from -8.9&#x000b1;3.2 to -5.0&#x000b1;4.4 (p = 0.0014). No improvement in PHES or CRT index was observed in the placebo group (-9.0&#x000b1;3.6 to -7.6&#x000b1;4.2, p = 0.22 and 1.7&#x000b1;0.5 to 1.8&#x000b1;0.5, p = 0.87).</p></sec><sec id="sec023"><title>Dropouts</title><p>The overall dropout rate was 25% (n = 11) and thus 5% larger than expected. Nine (40%) dropped out in the group randomized to active invention and two (9%) in the placebo group (p = 0.08). Patient characteristics and reasons for dropout are listed in <xref ref-type="table" rid="pone.0185412.t005">Table 5</xref>. A post hoc sensitivity analysis considering all dropouts showed that the results would have been the same if none had dropped out: in a best-case scenario all dropouts would have experienced improvement similar to that of the patients on active intervention and these patients still improved the most (p = 0.04). In the worst-case scenario, all dropouts would have improved corresponding to the average placebo CRT index change and, in this case, the difference between the groups was still significant (p = 0.03).</p><table-wrap id="pone.0185412.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0185412.t005</object-id><label>Table 5</label><caption><title>Dropout characteristics.</title></caption><alternatives><graphic id="pone.0185412.t005g" xlink:href="pone.0185412.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1"/><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">Entry CRT</th><th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">Entry PHES</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">MELD score</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Child Pugh<break/>Score</th><th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Reason for drop out</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Active anti HE treatment</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">-5</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">12C</td><td align="left" rowspan="1" colspan="1">OHE</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">-11</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">9B</td><td align="left" rowspan="1" colspan="1">Orthopaedic hospital admission</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">-15</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">11C</td><td align="left" rowspan="1" colspan="1">Dead</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">-5</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">7B</td><td align="left" rowspan="1" colspan="1">Adverse effects</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">-2</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">5A</td><td align="left" rowspan="1" colspan="1">Adverse effects</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">-4</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">7B</td><td align="left" rowspan="1" colspan="1">No reason given</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">-7</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">6A</td><td align="left" rowspan="1" colspan="1">No reason given</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">-7</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">8B</td><td align="left" rowspan="1" colspan="1">No reason given</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">9B</td><td align="left" rowspan="1" colspan="1">No reason given</td></tr><tr><td align="left" colspan="6" rowspan="1">Placebo</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">9B</td><td align="left" rowspan="1" colspan="1">Died from previously diagnosed heart failure</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">-4</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">6A</td><td align="left" rowspan="1" colspan="1">OHE</td></tr></tbody></table></alternatives></table-wrap></sec></sec></sec><sec sec-type="conclusions" id="sec024"><title>Discussion</title><p>The purpose of this pilot study was to evaluate if the CRT test is able to detect and predict an effect of anti-HE-treatment. The central finding was that the cirrhosis patients without manifest HE and with an abnormal CRT index normalized or improved their psychometric status i.e. CRT index (and PHES) with three months of triple-active anti-HE intervention&#x02014;this did not occur in any other study group. The clinical implication of this finding it is that the CRT test might be useful in detecting an effect of anti-HE treatment (and useful in identifying cirrhosis patients who will benefit cognitively from anti-HE treatment). The test thus could be used both in the daily clinic and as an outcome measure in future scientific studies.</p><p>The methodological novelty of our study is that we used the effects of reportedly efficient therapeutic interventions in a randomized controlled fashion as a means to validate the meaningfulness of the CRT method in the management of MHE. Our primary outcome was the changes in psychometry i.e. the CRT index whereas we did <italic>not</italic> primarily aim to test the intervention effect. To secure the presence or non-presence of the desired psychometric signal, we applied the expectedly most powerful anti-HE intervention viz. the multi-modal triple modality. It is possible that we would have reached the same result with lactulose as a mono-intervention as there is now evidence that lactulose does ameliorate MHE, albeit the diagnostic methods vary among studies [<xref rid="pone.0185412.ref003" ref-type="bibr">3</xref>]. The current HE management guidelines do not recommend routine anti-MHE treatment likely due to uncertainty regarding which patients who would benefit from it [<xref rid="pone.0185412.ref020" ref-type="bibr">20</xref>]. The results for our study may improve this lack of decision basis when it comes to the CRT test; and demonstrate a methodological approach that could be useful in a similar validation of other psychometric tests for MHE. The ability of the CRT test to predict a treatment response, however, still does not solve the basic issue of establishing a gold standard for the diagnosis of MHE.</p><p>Additionally, the comparator measure, the PSE, improved in the group randomized to active intervention as whole (<xref ref-type="table" rid="pone.0185412.t003">Table 3</xref>) and the same effect was observed in the subgroup with an abnormal entry CRT index. Furthermore, in the secondary analysis, the patients with an abnormal entry PSE who were on active intervention also improved their CRT index and PHES. Although this was not a defined study outcome, it may illustrate that the PSE results, despite being somewhat discordant from the CRT results, may also be of use in identifying patients who would benefit from anti-HE intervention. Still, the PSE did not normalize on a group level, unlike the CRT index [<xref rid="pone.0185412.ref010" ref-type="bibr">10</xref>]. These results may be used to support the basic concept of the clinical utility of psychometry.</p><p>No other psychometric validation study within this research field is based on the same approach. It is noteworthy that the patients with an abnormal CRT index who received the placebo intervention tended to improve their CRT index&#x02014;only less so than the patients on the active intervention (by average 0.25 vs. 0.92). This illustrates the time-dependence of the cognitive disturbances cause by MHE and emphasizes the necessity for randomized intervention for evaluation of the test. As could be expected, there were no such temporal dynamics in the patients with a normal entry CRT index.</p><p>Our salient result was obtained in the small group of patients with an abnormal entry CRT index and randomized to active intervention. However, it was statistically significant and based on the <italic>a priori</italic> assumptions after which the study was dimensioned. Its robustness is supported by the fact that the outcome effect was more than threefold larger than the intra-individual day-to-day CRT index variability that we measured. It also supports the CRT index improvements being paralleled by the PSE test. The mechanistic role of ammonia is equivocal but, if anything, it is in support of our results that the group with the improvement in CRT index was the also the one in which ammonia decreased. We do, however, have a weakness due to the small sample sizes of the groups where no significant results were obtained. In these, the lack of signal might be caused by chance, although the negative results can be taken to have the power assumed in the <italic>a priori</italic> power calculation since there were only few dropouts in these groups.</p><p>The total number of dropouts was higher than assumed, but the sensitivity analyses still showed this did not threaten the study conclusions. The stratification after the entry CRT index did not predict dropout, but randomization to the active intervention did predict dropout. As usual, the most common complaint was bowel discomfort, but for those who chose to continue in the protocol, the complaints diminished within 7&#x02013;10 days. No serious adverse event was reported.</p><p>We did not observe any change in disease related quality of life in either group or strata. This contrasted with prior studies [<xref rid="pone.0185412.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0185412.ref023" ref-type="bibr">23</xref>] and the discrepancy was most likely related to our small study groups.</p><p>In summary, we showed that, in patients with cirrhosis and without manifest HE, an abnormal CRT index seemed to identify those patients who proved to cognitively normalize or improve with multimodal anti-HE intervention. Our findings needs confirmation in larger studies but indicate that the CRT test may be useful in selecting cirrhosis patients for treatment for MHE&#x02014;a frequent and debilitating complication. Further, our methodological approach could be useful in a similar validation of other psychometric tests.</p></sec><sec sec-type="supplementary-material" id="sec025"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0185412.s001"><label>S1 Text</label><caption><title>Protocol summary.</title><p>(PDF)</p></caption><media xlink:href="pone.0185412.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0185412.s002"><label>S2 Text</label><caption><title>Full protocol.</title><p>(PDF)</p></caption><media xlink:href="pone.0185412.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0185412.s003"><label>S1 Data</label><caption><title>Main RCT data.</title><p>(XLS)</p></caption><media xlink:href="pone.0185412.s003.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0185412.s004"><label>S2 Data</label><caption><title>All reproducibility data.</title><p>(XLSX)</p></caption><media xlink:href="pone.0185412.s004.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0185412.s005"><label>S1 Table</label><caption><title>Consort 2010 Checklist.</title><p>(DOC)</p></caption><media xlink:href="pone.0185412.s005.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0185412.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Maldonado-Garza</surname><given-names>HJ</given-names></name>, <name><surname>Vazquez-Elizondo</surname><given-names>G</given-names></name>, <name><surname>Gaytan-Torres</surname><given-names>JO</given-names></name>, <name><surname>Flores-Rendon</surname><given-names>AR</given-names></name>, <name><surname>Cardenas-Sandoval</surname><given-names>MG</given-names></name>, <name><surname>Bosques-Padilla</surname><given-names>FJ</given-names></name>. <article-title>Prevalence of minimal hepatic encephalopathy in cirrhotic patients</article-title>. <source>Ann Hepatol</source>. <year>2011</year>;<volume>10</volume>
<issue>Suppl 2</issue>:<fpage>S40</fpage>&#x02013;<lpage>4</lpage>. Epub 2012/01/18. doi: 951128 [pii]. .<pub-id pub-id-type="pmid">22228880</pub-id></mixed-citation></ref><ref id="pone.0185412.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>YY</given-names></name>, <name><surname>Nie</surname><given-names>YQ</given-names></name>, <name><surname>Sha</surname><given-names>WH</given-names></name>, <name><surname>Zeng</surname><given-names>Z</given-names></name>, <name><surname>Yang</surname><given-names>FY</given-names></name>, <name><surname>Ping</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China</article-title>. <source>World J Gastroenterol</source>. <year>2004</year>;<volume>10</volume>(<issue>16</issue>):<fpage>2397</fpage>&#x02013;<lpage>401</lpage>. Epub 2004/07/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3748/wjg.v10.i16.2397">10.3748/wjg.v10.i16.2397</ext-link></comment> .<pub-id pub-id-type="pmid">15285027</pub-id></mixed-citation></ref><ref id="pone.0185412.ref003"><label>3</label><mixed-citation publication-type="book"><name><surname>Gluud</surname><given-names>LL</given-names></name>, <name><surname>Vilstrup</surname><given-names>H</given-names></name>, <name><surname>Morgan</surname><given-names>MY</given-names></name>. <chapter-title>The effect of treatment for hepatic encephalopathy with nonabsorbable disaccarides on morbidity and mortality in patients with cirrhosis: Systematic review and meta-analysis</chapter-title> In: <name><surname>Jalan</surname><given-names>R</given-names></name>, editor. <source>EASL International Liver Congress 2015</source>; <publisher-loc>Vienna</publisher-loc>
<publisher-name>ILC 2015 Absctract Book: EASL</publisher-name>; <year>2015</year>. p. 175.</mixed-citation></ref><ref id="pone.0185412.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Lauridsen</surname><given-names>MM</given-names></name>, <name><surname>Bajaj</surname><given-names>JS</given-names></name>. <article-title>Hepatic Encephalopathy Treatment and Driving: A Continental Divide</article-title>. <source>J Hepatol</source>. <year>2015</year>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jhep.2015.03.017">10.1016/j.jhep.2015.03.017</ext-link></comment> .<pub-id pub-id-type="pmid">25796480</pub-id></mixed-citation></ref><ref id="pone.0185412.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Weissenborn</surname><given-names>K</given-names></name>. <article-title>Psychometric tests for diagnosing minimal hepatic encephalopathy</article-title>. <source>Metab Brain Dis</source>. <year>2012</year> Epub 2012/09/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11011-012-9336-4">10.1007/s11011-012-9336-4</ext-link></comment> .<pub-id pub-id-type="pmid">22993201</pub-id></mixed-citation></ref><ref id="pone.0185412.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Lauridsen</surname><given-names>MM</given-names></name>, <name><surname>Jepsen</surname><given-names>P</given-names></name>, <name><surname>Vilstrup</surname><given-names>H</given-names></name>. <article-title>Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease</article-title>. <source>Metab Brain Dis</source>. <year>2011</year>;<volume>26</volume>(<issue>2</issue>):<fpage>135</fpage>&#x02013;<lpage>9</lpage>. Epub 2011/04/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11011-011-9242-1">10.1007/s11011-011-9242-1</ext-link></comment> .<pub-id pub-id-type="pmid">21484318</pub-id></mixed-citation></ref><ref id="pone.0185412.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Goldbecker</surname><given-names>A</given-names></name>, <name><surname>Weissenborn</surname><given-names>K</given-names></name>, <name><surname>Hamidi Shahrezaei</surname><given-names>G</given-names></name>, <name><surname>Afshar</surname><given-names>K</given-names></name>, <name><surname>Rumke</surname><given-names>S</given-names></name>, <name><surname>Barg-Hock</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates</article-title>. <source>Gut</source>. <year>2013</year>;<volume>62</volume>(<issue>10</issue>):<fpage>1497</fpage>&#x02013;<lpage>504</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/gutjnl-2012-303262">10.1136/gutjnl-2012-303262</ext-link></comment> .<pub-id pub-id-type="pmid">23297006</pub-id></mixed-citation></ref><ref id="pone.0185412.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Gluud</surname><given-names>LL</given-names></name>, <name><surname>Dam</surname><given-names>G</given-names></name>, <name><surname>Les</surname><given-names>I</given-names></name>, <name><surname>Cordoba</surname><given-names>J</given-names></name>, <name><surname>Marchesini</surname><given-names>G</given-names></name>, <name><surname>Borre</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Branched-chain amino acids for people with hepatic encephalopathy</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2015</year>;<volume>2</volume>:<fpage>CD001939</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/14651858.CD001939.pub2">10.1002/14651858.CD001939.pub2</ext-link></comment> .<pub-id pub-id-type="pmid">25715177</pub-id></mixed-citation></ref><ref id="pone.0185412.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Kimer</surname><given-names>N</given-names></name>, <name><surname>Krag</surname><given-names>A</given-names></name>, <name><surname>Moller</surname><given-names>S</given-names></name>, <name><surname>Bendtsen</surname><given-names>F</given-names></name>, <name><surname>Gluud</surname><given-names>LL</given-names></name>. <article-title>Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2014</year>;<volume>40</volume>(<issue>2</issue>):<fpage>123</fpage>&#x02013;<lpage>32</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/apt.12803">10.1111/apt.12803</ext-link></comment> .<pub-id pub-id-type="pmid">24849268</pub-id></mixed-citation></ref><ref id="pone.0185412.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Lauridsen</surname><given-names>MM</given-names></name>, <name><surname>Schaffalitzky de Muckadell</surname><given-names>OB</given-names></name>, <name><surname>Vilstrup</surname><given-names>H</given-names></name>. <article-title>Minimal hepatic encephalopathy characterized by parallel use of the continuous reaction time and portosystemic encephalopathy tests</article-title>. <source>Metab Brain Dis</source>. <year>2015</year>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11011-015-9688-7">10.1007/s11011-015-9688-7</ext-link></comment> .<pub-id pub-id-type="pmid">26016624</pub-id></mixed-citation></ref><ref id="pone.0185412.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Lauridsen</surname><given-names>MM</given-names></name>, <name><surname>Thiele</surname><given-names>M</given-names></name>, <name><surname>Kimer</surname><given-names>N</given-names></name>, <name><surname>Vilstrup</surname><given-names>H</given-names></name>. <article-title>The continuous reaction times method for diagnosing, grading, and monitoring minimal/covert hepatic encephalopathy</article-title>. <source>Metab Brain Dis</source>. <year>2013</year> Epub 2013/01/10. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11011-012-9373-z">10.1007/s11011-012-9373-z</ext-link></comment> .<pub-id pub-id-type="pmid">23299303</pub-id></mixed-citation></ref><ref id="pone.0185412.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Lauridsen</surname><given-names>MM</given-names></name>, <name><surname>Gronbaek</surname><given-names>H</given-names></name>, <name><surname>Naeser</surname><given-names>EB</given-names></name>, <name><surname>Leth</surname><given-names>ST</given-names></name>, <name><surname>Vilstrup</surname><given-names>H</given-names></name>. <article-title>Gender and age effects on the continuous reaction times method in volunteers and patients with cirrhosis</article-title>. <source>Metab Brain Dis</source>. <year>2012</year> Epub 2012/05/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11011-012-9318-6">10.1007/s11011-012-9318-6</ext-link></comment> .<pub-id pub-id-type="pmid">22614824</pub-id></mixed-citation></ref><ref id="pone.0185412.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Bankhead</surname><given-names>I</given-names></name>, <name><surname>MacKay</surname><given-names>DN</given-names></name>. <article-title>Fine motor performance in subjects of subnormal, normal and superior intelligence. I. Reaction time and task complexity</article-title>. <source>J Ment Defic Res</source>. <year>1982</year>;<volume>26</volume> (<issue>Pt 2</issue>):<fpage>73</fpage>&#x02013;<lpage>89</lpage>. Epub 1982/06/01. .<pub-id pub-id-type="pmid">7108947</pub-id></mixed-citation></ref><ref id="pone.0185412.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Renzi</surname><given-names>D</given-names></name>. <article-title>The comparative efficiency of intelligence and vigilance tests in detecting hemispheric cerebral damage</article-title>. <source>Cortex</source>. <year>1965</year>;<volume>1</volume>:<fpage>410</fpage>&#x02013;<lpage>33</lpage>.</mixed-citation></ref><ref id="pone.0185412.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Lally</surname><given-names>M</given-names></name>, <name><surname>Nettelbeck</surname><given-names>T</given-names></name>. <article-title>Intelligence, reaction time, and inspection time</article-title>. <source>Am J Ment Defic</source>. <year>1977</year>;<volume>82</volume>(<issue>3</issue>):<fpage>273</fpage>&#x02013;<lpage>81</lpage>. Epub 1977/11/01. .<pub-id pub-id-type="pmid">930964</pub-id></mixed-citation></ref><ref id="pone.0185412.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Elsass</surname><given-names>P</given-names></name>, <name><surname>Christensen</surname><given-names>SE</given-names></name>, <name><surname>Mortensen</surname><given-names>EL</given-names></name>, <name><surname>Vilstrup</surname><given-names>H</given-names></name>. <article-title>Discrimination between organic and hepatic encephalopathy by means of continuous reaction times</article-title>. <source>Liver</source>. <year>1985</year>;<volume>5</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>34</lpage>. Epub 1985/02/01. .<pub-id pub-id-type="pmid">3982241</pub-id></mixed-citation></ref><ref id="pone.0185412.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Schomerus</surname><given-names>H</given-names></name>, <name><surname>Hamster</surname><given-names>W</given-names></name>. <article-title>Neuropsychological aspects of portal-systemic encephalopathy</article-title>. <source>Metab Brain Dis</source>. <year>1998</year>;<volume>13</volume>(<issue>4</issue>):<fpage>361</fpage>&#x02013;<lpage>77</lpage>. .<pub-id pub-id-type="pmid">10206827</pub-id></mixed-citation></ref><ref id="pone.0185412.ref018"><label>18</label><mixed-citation publication-type="book"><name><surname>Hulley</surname><given-names>SB</given-names></name>, <name><surname>Cummings</surname><given-names>S.R.</given-names></name>, <name><surname>Browner</surname><given-names>W.S.</given-names></name>, <name><surname>Grady</surname><given-names>D.</given-names></name>, <name><surname>Newman</surname><given-names>T.B</given-names></name>. <chapter-title>Designing Clinical Research: an Epidemiologic Approach</chapter-title>
<edition>4th ed</edition>: <publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="pone.0185412.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Shapiro</surname><given-names>SS</given-names></name>, <name><surname>Wilk</surname><given-names>MB</given-names></name>. <article-title>An analysis of variance test for normality (complete samples)&#x02020;</article-title>. <source>Biometrika</source>. <year>1965</year>;<volume>52</volume>(<issue>3&#x02013;4</issue>):<fpage>591</fpage>&#x02013;<lpage>611</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/biomet/52.3&#x02013;4.591">10.1093/biomet/52.3&#x02013;4.591</ext-link></comment></mixed-citation></ref><ref id="pone.0185412.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Vilstrup</surname><given-names>H</given-names></name>, <name><surname>Amodio</surname><given-names>P</given-names></name>, <name><surname>Bajaj</surname><given-names>J</given-names></name>, <name><surname>Cordoba</surname><given-names>J</given-names></name>, <name><surname>Ferenci</surname><given-names>P</given-names></name>, <name><surname>Mullen</surname><given-names>KD</given-names></name>, <etal>et al</etal>
<article-title>Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver</article-title>. <source>Hepatology</source>. <year>2014</year>;<volume>60</volume>(<issue>2</issue>):<fpage>715</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/hep.27210">10.1002/hep.27210</ext-link></comment> .<pub-id pub-id-type="pmid">25042402</pub-id></mixed-citation></ref><ref id="pone.0185412.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Sidhu</surname><given-names>SS</given-names></name>, <name><surname>Goyal</surname><given-names>O</given-names></name>, <name><surname>Mishra</surname><given-names>BP</given-names></name>, <name><surname>Sood</surname><given-names>A</given-names></name>, <name><surname>Chhina</surname><given-names>RS</given-names></name>, <name><surname>Soni</surname><given-names>RK</given-names></name>. <article-title>Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial)</article-title>. <source>Am J Gastroenterol</source>. <year>2011</year>;<volume>106</volume>(<issue>2</issue>):<fpage>307</fpage>&#x02013;<lpage>16</lpage>. Epub 2010/12/16. ajg2010455 [pii] <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ajg.2010.455">10.1038/ajg.2010.455</ext-link></comment> .<pub-id pub-id-type="pmid">21157444</pub-id></mixed-citation></ref><ref id="pone.0185412.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Mittal</surname><given-names>VV</given-names></name>, <name><surname>Sharma</surname><given-names>BC</given-names></name>, <name><surname>Sharma</surname><given-names>P</given-names></name>, <name><surname>Sarin</surname><given-names>SK</given-names></name>. <article-title>A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>2011</year>;<volume>23</volume>(<issue>8</issue>):<fpage>725</fpage>&#x02013;<lpage>32</lpage>. Epub 2011/06/08. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MEG.0b013e32834696f5">10.1097/MEG.0b013e32834696f5</ext-link></comment> .<pub-id pub-id-type="pmid">21646910</pub-id></mixed-citation></ref><ref id="pone.0185412.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Prasad</surname><given-names>S</given-names></name>, <name><surname>Dhiman</surname><given-names>RK</given-names></name>, <name><surname>Duseja</surname><given-names>A</given-names></name>, <name><surname>Chawla</surname><given-names>YK</given-names></name>, <name><surname>Sharma</surname><given-names>A</given-names></name>, <name><surname>Agarwal</surname><given-names>R</given-names></name>. <article-title>Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy</article-title>. <source>Hepatology</source>. <year>2007</year>;<volume>45</volume>(<issue>3</issue>):<fpage>549</fpage>&#x02013;<lpage>59</lpage>. Epub 2007/02/28. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/hep.21533">10.1002/hep.21533</ext-link></comment> .<pub-id pub-id-type="pmid">17326150</pub-id></mixed-citation></ref></ref-list></back></article>